Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy

BMC Musculoskeletal Disorders

Jaime Poquet Jornet¹  Nuria Franco Ferrando³  Rafael Sanjuan Cerveró² 

[1] Chief of the Clinical Department of Pharmacy, Health Department in Denia, Denia, Alicante, Spain;Hospital De Denia Marina Salud, Partida Beniadlà, S/N, Dénia, Alicante 03700, Spain;Orthopedics and Traumatology Surgery (OTS) Department of the Hospital de Denia, Denia, Alicante, Spain

关键词: Costs;    Collagenase Clostrodium histolyticum;    Dupuytren;   

Others  :  1129473
DOI  :  10.1186/1471-2474-14-293

 received in 2012-12-20, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Background

Our purpose was to analyze and compare the use of direct health resources and costs generated in the treatment of Dupuytren's contracture using two different techniques: subtotal fasciectomy and infiltration with Collagenase Clostridium Histolyticum (CCH) in regular clinical practice at the Orthopedic and Traumatology Surgery (OTS) Department at the Hospital de Denia (Spain).

Methods

Observational, retrospective study based on data from the computerized clinical histories of two groups of patients- those treated surgically using a one or two digit subtotal fasciectomy technique (FSC) and those treated with CCH infiltration, monitored in regular clinical practice from February, 2009 to May, 2012. Demographic (age, sex), clinical (number of digits affected and which ones) and use of resources (hospitalizations, medical visits, tests and drugs) data were collected. Resource use and associated costs, according to the hospital’s accounting department, were compared based on the type of treatment from Spain’s National Health Service.

Results

91 patients (48 (52.8%) in the FSC group) were identified. The average age and number of digits affected was 65.9 (9.2) years and 1.33 (0.48) digits affected in the FSC group, and 65.1 (9.7) years and 1.16 (0.4) digits in the CCH group.

Overall, the costs of treating Dupuytren's disease with subtotal FSC amount to €1,814 for major ambulatory surgery and €1,961 with hospital stay including admission, surgical intervention (€904), examinations, dressings and physiotherapy. As to collagenase infiltration, costs amount to €952 (including minor surgery admission, vial with product, office examination and dressings). Finally, comparing total costs for treatments, a savings of €388 is estimated in favor of CCH treatment in the best-case scenario (patient under MAS system with no need for physiotherapy) and €1,008 in the worst-case scenario (patient admitted to hospital needing subsequent physiotherapy), implying a savings of 29% and 51%, respectively.

Conclusions

This study demonstrates that treating patients with DC by injection with CCH at the OTS department of the Hospital de Denia generates a total savings of 29% and 51% (€388 and €1008) compared with fasciectomy at the time of treatment. Long term evolution of CCH treatment is uncertain and the recurrence rate unknown.

【 授权许可】

   
2013 Sanjuan Cerveró et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Guillaume Dupuytren (1777–1835) after publishing the first edition of Leçons Orales. 1832.
• [2]Behrooz Mostofi S: Who’s who in Orthopedics. 1st edition. London: Springer-Verlag; 2005:89-92.
• [3]Al-Qattan MM: Factors in the pathogenesis of Dupuytren’s contracture. J Hand Surg Am 2006, 31:1527-1534.
• [4]Ross DC: Epidemiology of Dupuytren's disease. Hand Clin 1999, 15:53-62.
• [5]Brenner P, Mailander P, Berger A: Epidemiology of Dupuytren’s disease. In Dupuytren’s disease. Edited by Berger A, Delbrüsk A, Brenner P, Hinzmann R. Berlin: Sprinter-Verlag; 1994:244-254.
• [6]Beaudreuil J, Lellouche H, Roulot E, Orcel P, Bardin T: Maladie de Dupuytren. Edited by EMC (Elseiver Masson SAS). Paris: Appareil Locomoteur; 2011:14-068. A-10
• [7]Herrera Rodríguez A, Perez Garcia JM: Enfermedad de Dupuytren. In Monografías medico-quirúrgicas del aparato locomotor (Mano y muñeca). Edited by Hernandez Vaquero D, Torre Alonso JC. Barcelona: Editorial Masson; 1999:39-56.
• [8]Jacobsen K, Holst-Nielsen F: A modified McCash operation for Dupuytren´s contracture. Scand J Plast Reconstr Surg 1977, 11(3):231-233.
• [9]Rayan GM: Non-operative treatment of Dupuytren’s disease. J Hand Surg Am 2008, 33:1208-1210.
• [10]Desai SS: Hentz, VR: collagenase clostridium histolyticum for Dupuytren’s contracture. Expert Opin Biol Ther 2010, 10:1395-1404.
• [11]Maravic M, Landais P: Dupuytren's disease in France–1831 to 2001–from description to economic burden. J Hand Surg Br 2005, 30:484-487.
• [12]Zhang A, Curtin CM, Hentz VR: Flexor tendon rupture after collagenase injection for Dupuytren contracture: Case report. J Hand Surg Am 2011, 36:1323-1325.
• [13]Approval for use of Xiapex® in Europe. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002048/WC500103377.pdf webcite. Revised November 15
• [14]BSSH Evidence for Surgical Treatment: Dupuytren´s Disease. http://www.bssh.ac.uk/education/guidelines/dd_guidelines_2.pdf webcite
• [15]Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N: Injectable Collagenase Clostridium Histolyticum: a new nonsurgical treatment for Dupuytren’s disease. Hand Surg Am 2010, 35:2027-2038.
• [16]Tubiana R, Michon J, Thomine JM: Scheme for the assessment of deformities in Dupuytren´s disease. Surg Clin North Am 1968, 48:979-984.
• [17]Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, et al.: Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009, 361:968-679.
• [18]De Salas Cansado M, Ruiz Antoran MB, Ramírez E, Dudley A, et al.: Health care resource utilization and associated costs secondary to fasciectomy in Dupuytren disease in Spain. Farm Hosp 2013, 37:41-49.
• [19]Chen NC, Shauver MJ, Chung KC: Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg Am 2011, 36:1826-1834.
• [20]Gerber RA, Perry R, Thompson R, Bainbridge C: Dupuytren’s contracture: a retrospective database analysis to assess clinical management and costs in England. BMC Musculoskelet Disord 2011, 12:73. BioMed Central Full Text
• [21]Van Rijssen AL, Werker PM: Percutaneous needle fasciotomy in Dupuytren’s disease. J Hand Surg 2006, 31B:498-501.
• [22]Van Rijssen AL, Werker PM: Percutaneous needle fasciotomy for recurrent Dupuytren disease. J Hand Surg Am 2012, 37:1820-1823.
• [23]Badalamente MA, Hurst LC: Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am 2007, 32:767-774.
• [24]Watt AJ, Curtin CM, Hentz VR: Collagenase injection as nonsurgical treatment of Dupuytren’s disease: 8-year follow-up. J Hand Surg 2010, 35:534-539.
• [25]Stanbury SJ, Hammert WC: Dupuytren contracture. J Hand Surg Am 2011, 36A:2038-2040.
• [26]Armstrong JR, Hurren JS, Logan AM: Dermofasciectomy in the management of Dupuytren´s disease. J Bone Joint Surg Br 2000, 82B:90-94.
• [27]Citron N, Messina JC: The use of skeletal traction in the treatment of severe primary Dupuytren´s disease. J Bone Joint Surg Br 1998, 80B:126-129.
• [28]Legislative Decree: No. 1/2005, of February 25, 2005 by the Consell de la Generalitat Valenciana by means of which comes the revised text of the Ley de Tasas de la Generalitat. Titulo VI 2012, I:7321-7393. BOE-A-2012-1253. BOE of January 27
• [29]Chen NC, Sirinvasan RC, Shauver MJ, Chung KC: A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren’s contracture. Hand 2011, 6:250-255.
• [30]Drug and Terapeutics Bulletin: British national formulary 10.3.1. 2011, 49(12):138-141. In dtb.bmj.com